Immunome announces EMA validation of marketing authorization application for varegacestat to treat adults with desmoid tumors
IMNM•Immunome said the European Medicines Agency validated its marketing authorization application for varegacestat to treat adults with desmoid tumors. The application is supported by positive Phase 3 RINGSIDE results with statistically significant improvements.
1. Application validated
Immunome announced that the European Medicines Agency validated its marketing authorization application for varegacestat for the treatment of adults with desmoid tumors. The application is supported by positive Phase 3 RINGSIDE results with statistically significant improvements.
